Publications by authors named "Pisa Phiphitaporn"
Treatment outcomes between cyclosporin and chemotherapy in adult subcutaneous panniculitis-like T-cell lymphoma: a report from nation-wide Thai lymphoma study group registry.
Ann Hematol
December 2024
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of T-cell lymphomas with a characteristic feature of subcutaneous nodules associated with hemophagocytic lymphohistiocytosis (HLH). Treatment options for SPTCL are mainly chemotherapy (CMT) or immunosuppressive agents with selection currently dependent on physician decisions. Outcomes between the 2 treatment remedies have not yet been comprehensively compared.
View Article and Find Full Text PDFEndothelial activation and stress index as a prognostic factor of diffuse large B-cell lymphoma: the report from the nationwide multi-center Thai Lymphoma Study Group.
Ann Hematol
December 2023
Several prognostic models have been introduced to predict outcomes of patients with diffuse large B-cell lymphoma (DLBCL). Endothelial activation and stress index (EASIX) is a surrogate of endothelial dysfunction which has been shown to predict outcomes of patients with various hematologic malignancies. However, the prognostic implication of EASIX for DLBCL is limited and warrants exploration.
View Article and Find Full Text PDFOutcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
Ann Hematol
July 2023
Article Synopsis
- Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is tough to treat, and there's a need for better therapies; polatuzumab vedotin (Pola), combined with bendamustine-rituximab (BR), has recently been approved for patients.
- A study in Thailand included 35 patients treated with Pola, showing a 62.8% overall response rate (ORR) and survival outcomes better than 180 patients receiving non-Pola therapies.
- Despite some serious adverse events reported, they were manageable, indicating that Pola-based treatment could be a promising option for R/R DLBCL patients with limited alternatives.
Background: Ineffective erythropoiesis (IE) is a significant risk factor for osteoporosis in individuals with thalassemia. Growth differentiation factor-15 (GDF15), a biomarker of IE, was found to be elevated in thalassemia patients. This study aimed to examine the association between GDF15 levels and osteoporosis in patients with thalassemia.
View Article and Find Full Text PDFIntroduction: Chronic anemia, iron overload, and iron chelation therapy are the main contributing factors for renal complications in thalassemia, e.g., nephrolithiasis, glomerular disease, and renal tubular dysfunction.
View Article and Find Full Text PDFIntroduction: Patients with thalassemia increase the risk of developing cognitive impairment. Chronic anemia, oxidative stress from excess iron, and hypercoagulable state were related to this condition. The study regarding its prevalence and the associated factor in Southeast Asia is limited.
View Article and Find Full Text PDF